Saved source record
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
This is a source-metadata record last found in a complete check on Sep 28, 2026. It is not a Pependium assessment of safety or effectiveness. Check the original sources for current details, corrections and full methods.
Source status: This saved record has not yet had a scheduled exact-ID status check. Check its original source links.
Study metadata
- Study type
- Original study
- Study category (metadata hint)
- Human
- Source date
- Published: 2026-04-21
- Authors
- Johansson E, Wilding JPH, Upadhyay N, van Hest N, Kirk M, Spaepen E, Zimner-Rapuch S, Annemans L
- Journal or registry
- Not reported
- Registry study design
- Not reported
- Registry enrollment
- Not reported
- Funding agencies
- Eli Lilly and Company
- Identifiers
- DOI: 10.1080/13696998.2026.2646078 · PMID: 42012820
- First found
- Sep 28, 2026
- Last found
- Sep 28, 2026
Original sources
Browse saved studies · Search live sources